Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy

• Status: Terminated
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Blood loss was reported as a prognostic risk factor of morbidity and overall survival after hepatic resection. The aim of this study prospective randomized was compare the efficacy of the administration of tranexamic acid versus placebo to reduce perioperative bleeding after major hepatectomy (> 3 hepatic segments).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Strasbourg, France
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Signature of the consent form

• Patients with hepatic lesion needing a major hepatectomy (≥ 3 hepatic segments)

Exclusion Criteria:

• Absence of signature of the consent form

• Patient with cirrhosis

• Minor hepatectomy (< 3 hepatic segments)

• Hepatectomy associated with vascular resection

• Contraindication of tranexamic acid : history of arterial or venous thrombosis , disseminated intravascular coagulation, severe renal insufficiency, history of epilepsies , intrathecal or intraventricular injection

• Pregnant or lactation